FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947560779> ?p ?o ?g. }

• W2947560779 abstract "e20717 Background: Place of care may be an important factor affecting treatment & economic outcomes for pts in advanced stages of cancer. This retrospective observational study compared treatment patterns, healthcare resource use & costs, and overall survival (OS) for pts treated for selected cancers in the hospital outpatient department (HO) vs community oncology practices (CP) including physician offices & freestanding ambulatory centers. Methods: Claims data from a large national health plan were used to identify adult pts with newly diagnosed advanced/metastatic non small cell lung cancer (aNSCLC), metastatic breast (mBC) or metastatic colorectal cancer (mCRC) between 07/2012 & 12/2016, who initiated anticancer therapy in HO or CP settings. Pts enrolled in Medicare Advantage Prescription Drug (MAPD) or commercial plans for ≥ 6 months prior & ≥ 30 days after start of first line (1L) (index date) were included. OS was evaluated among pts enrolled in MAPD and costs were evaluated among pts enrolled ≥ 6 months pre- & post-index, by cancer type & by place of care. Outcome analyses were adjusted using multivariable models. Results: Among 8,333 eligible pts, there were 4,618, 2,304 & 1,411 pts with aNSCLC, mCRC & mBC, respectively and each cohort was evenly split by place of care. No notable differences in baseline characteristics or the most commonly used 1L, 2L or 3L regimens were observed by place of care for the 3 cancers. For aNSCLC pts, mean 1L treatment duration was shorter (96 v 102 days, P = 0.02) and time between 1L & 2L was longer (125 v 106 days, P = 0.04) in the HO than the CP setting, respectively. For mBC, mean 1L treatment duration was longer in the HO setting (156 v 190 days, P < 0.01). Adjusted total all cause healthcare costs were higher in HO than CP for mBC ( P < 0.01) & mCRC ( P < 0.01), but no significant difference in median OS was observed between HO & CP settings for the 3 cancer types. Conclusions: This study showed no major differences between HO & CP settings in baseline characteristics, the first 3 lines of therapy, or adjusted median OS for aNSCLC, mCRC, or mBC cohorts. However, total costs were higher in the HO setting for mCRC & mBC pts. These findings may be useful for healthcare decision & policy makers but warrant further evaluation." @default.
• W2947560779 created "2019-06-07" @default.
• W2947560779 creator A5004893155 @default.
• W2947560779 creator A5006683352 @default.
• W2947560779 creator A5018460766 @default.
• W2947560779 creator A5031117797 @default.
• W2947560779 creator A5031548464 @default.
• W2947560779 creator A5057847937 @default.
• W2947560779 creator A5065226420 @default.
• W2947560779 creator A5086717035 @default.
• W2947560779 creator A5091740623 @default.
• W2947560779 date "2019-05-20" @default.
• W2947560779 modified "2023-09-23" @default.
• W2947560779 title "Treatment and outcomes for patients (pts) with selected advanced/metastatic cancers by place of care." @default.
• W2947560779 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e20717" @default.
• W2947560779 hasPublicationYear "2019" @default.
• W2947560779 type Work @default.
• W2947560779 sameAs 2947560779 @default.
• W2947560779 citedByCount "0" @default.
• W2947560779 crossrefType "journal-article" @default.
• W2947560779 hasAuthorship W2947560779A5004893155 @default.
• W2947560779 hasAuthorship W2947560779A5006683352 @default.
• W2947560779 hasAuthorship W2947560779A5018460766 @default.
• W2947560779 hasAuthorship W2947560779A5031117797 @default.
• W2947560779 hasAuthorship W2947560779A5031548464 @default.
• W2947560779 hasAuthorship W2947560779A5057847937 @default.
• W2947560779 hasAuthorship W2947560779A5065226420 @default.
• W2947560779 hasAuthorship W2947560779A5086717035 @default.
• W2947560779 hasAuthorship W2947560779A5091740623 @default.
• W2947560779 hasConcept C126322002 @default.
• W2947560779 hasConcept C143998085 @default.
• W2947560779 hasConcept C177713679 @default.
• W2947560779 hasConcept C71924100 @default.
• W2947560779 hasConceptScore W2947560779C126322002 @default.
• W2947560779 hasConceptScore W2947560779C143998085 @default.
• W2947560779 hasConceptScore W2947560779C177713679 @default.
• W2947560779 hasConceptScore W2947560779C71924100 @default.
• W2947560779 hasLocation W29475607791 @default.
• W2947560779 hasOpenAccess W2947560779 @default.
• W2947560779 hasPrimaryLocation W29475607791 @default.
• W2947560779 hasRelatedWork W1579308467 @default.
• W2947560779 hasRelatedWork W2104255363 @default.
• W2947560779 hasRelatedWork W2121875608 @default.
• W2947560779 hasRelatedWork W2159110717 @default.
• W2947560779 hasRelatedWork W2345269212 @default.
• W2947560779 hasRelatedWork W2421500157 @default.
• W2947560779 hasRelatedWork W2590761874 @default.
• W2947560779 hasRelatedWork W2890730399 @default.
• W2947560779 hasRelatedWork W2903853567 @default.
• W2947560779 hasRelatedWork W2944429361 @default.
• W2947560779 hasRelatedWork W2947455576 @default.
• W2947560779 hasRelatedWork W2952269319 @default.
• W2947560779 hasRelatedWork W2964904991 @default.
• W2947560779 hasRelatedWork W2966656938 @default.
• W2947560779 hasRelatedWork W2977850564 @default.
• W2947560779 hasRelatedWork W3004472340 @default.
• W2947560779 hasRelatedWork W3004866432 @default.
• W2947560779 hasRelatedWork W3017304853 @default.
• W2947560779 hasRelatedWork W3025637178 @default.
• W2947560779 hasRelatedWork W593255130 @default.
• W2947560779 isParatext "false" @default.
• W2947560779 isRetracted "false" @default.
• W2947560779 magId "2947560779" @default.
• W2947560779 workType "article" @default.